Biotech Industry Looks to Benefit From New Legislation Passed to Help Speed Up FDA Review Process

The Paragon Report Provides Stock Research on StemCells and ImmunoCellular

Marketwired

NEW YORK, NY--(Marketwire - Sep 10, 2012) - Despite concerns of a global economic slowdown the Biotech Industry has impressed investors with strong gains in 2012. Patent expirations, favorable legislation, and a faster review process have been some of the contributing factors for the industry's current boom. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on StemCells, Inc. (NASDAQ: STEM) and ImmunoCellular Therapeutics Ltd. (NYSE: IMUC).

Access to the full company reports can be found at:
www.ParagonReport.com/STEM
www.ParagonReport.com/IMUC

The Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law on July 9, 2012 by President Obama. The law allows the FDA to collect "user fees" to help fund reviews of innovator drugs, medical devices, generic drugs and biosimilars.

"The legislation will enhance the development and review of innovative new therapies through increased transparency and scientific dialogue, advancements in regulatory science and strengthened post-market review. It will also increase the Food and Drug Administration's (FDA) access to external expertise to improve the drug review process," Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood said in a statement.

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

StemCells is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC cells, is currently in development as a potential treatment for a broad range of central nervous system disorders. The company was recently initiated with a "buy" rating at and a price target of $2.50.

ImmunoCellular Therapeutics is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. Shares of the company surged over 10 percent last Thursday after the Maxim Group gave the company a "buy" rating and price target of $18.00.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
http://www.paragonreport.com/disclaimer

Rates

View Comments (1)